Financing ·
ProQR Therapeutics N.V. reported second quarter 2026 financial results and provided a business update
PRQRProQR Therapeutics N.V.
ProQR Therapeutics N.V. reported second quarter 2026 financial results and provided a business update. The company closed an underwritten registered direct offering of $50.0 million alongside a concurrent private placement with Eli Lilly for $9.2 million, totaling approximately $59.2 million in gross proceeds. This financing strengthened the balance sheet, ending Q2 2026 with €117.1 million in cash and cash equivalents, supporting operations through mid-2028. Net loss for the quarter was €8.7 million, or €0.08 per diluted share, compared to a net loss of €12.2 million, or €0.12 per diluted share, in the same period last year. R&D costs were €12.7 million and general and administrative costs were €4.9 million. Clinically, ProQR announced positive AX-0810 Phase 1 target engagement data establishing first clinical validation of its Axiomer RNA editing platform for NTCP modulation. The company also submitted a Clinical Trial Application to the EMA for AX-0811, with initial data expected by year-end 2026. ProQR Therapeutics is a clinical-stage biotechnology company developing transformative RNA therapies using its proprietary Axiomer RNA editing technology.